At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 14 enrolled
Drug / intervention
installation of D. pteronyssinus allergensbiological
Likely dose
installation of D. pteronyssinus allergens 5 mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Role of the Isomerase Pin-1 in the Development and Treatment of Asthma
In Brief
A Phase 2 clinical trial evaluating installation of D. pteronyssinus allergens for Asthma. Completed, enrolled 14 participants across 1 site.
Detailed Summary
Pin1 is activated in asthmatic airways, increasing cytokine mRNA stability and eosinophil survival. This study is designed to test whether the Pin1 enzyme regulates TLR/IL-1R signal pathways in multiple cells in asthma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedSep 2012
Enrollment StartMar 2013
Primary CompletionMay 2015
TodayJul 2026
First PostedSep 25, 2012
Enrollment StartMar 1, 2013
Primary CompletionMay 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 13.8 years ago
Interventions
installation of D. pteronyssinus allergensbiological
We will perform bronchoscopy and segmental allergen challenges. Subjects will undergo bronchoscopy with segmental installation of 5 ml of D. pteronyssinus (DerP). BAL and lung biopsy of the allergen-challenged segments will be performed 48 hr later